INSANE: What to expect from moderna s q1 2025 earnings report | Vintage Vibes

Valued at a market cap of $9.6 billion, Cambridge, Massachusetts-based Moderna, Inc. (MRNA) is a biotechnology company that focuses on developing messenger RNA (mRNA) medicines and vaccines. Best known for its COVID-19 vaccine, Spikevax, Moderna also has a broad pipeline targeting respiratory, latent, and enteric viruses, as well as cancer and rare diseases. MRNA is expected to release its fiscal Q1 2025 earnings results before the market opens on Thursday, May 1. 

Ahead of this event, analysts expect the biotechnology company to report a loss of $2.91 per share, up 5.2% from a loss of $3.07 per share in the prior year's quarter. It has surpassed Wall Street's bottom-line estimates in the past four quarters. In Q4 2024, Moderna exceeded the consensus EPS estimate by 7.1%.